BioCryst Pharmaceuticals saw the highest growth of 2.49% in patent filings in May and 0.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.66% and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of BioCryst Pharmaceuticals‘s patent filings and grants. Buy the databook here.
Smarter leaders trust GlobalData
BioCryst Pharmaceuticals has been focused on protecting inventions in United States(US) with four publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 43% filings and 12% grants. The United States(US), European Patent Office(EPO), South Korea(KR), and Chile(CL) patent Office are among the top ten patent offices where BioCryst Pharmaceuticals is filings its patents. Among the top granted patent authorities, BioCryst Pharmaceuticals has 38% of its grants in Israel(IL), 12% in United States(US) and 12% in European Patent Office(EPO).
Bayer and Vertex Pharmaceuticals could be the strongest competitors for BioCryst Pharmaceuticals
In terms of grant share, BioCryst Pharmaceuticals stands in seventh position among its competitors. Bayer and Vertex Pharmaceuticals secured the top positions according to recent patent publication data.
Patents related to rare diseases and health & wellness lead BioCryst Pharmaceuticals's portfolio
BioCryst Pharmaceuticals has the highest number of patents in rare diseases followed by, health & wellness and climate change. For rare diseases, nearly 80% of patents were filed and 50% of patents were granted in Q2 2024.
Fibrodysplasia ossificans progressiva (myositis ossificans progressiva) related patents lead BioCryst Pharmaceuticals portfolio followed by angioedema, and hereditary angioedema (hae) (c1 esterase inhibitor [c1-inh] deficiency)
BioCryst Pharmaceuticals has highest number of patents in fibrodysplasia ossificans progressiva (myositis ossificans progressiva) followed by angioedema, hereditary angioedema (hae) (c1 esterase inhibitor [c1-inh] deficiency), diabetic retinopathy, and diabetic macular edema. For fibrodysplasia ossificans progressiva (myositis ossificans progressiva), nearly 4% of patents were filed and 20% of patents were granted in Q2 2024.
For comprehensive analysis of BioCryst Pharmaceuticals's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.
Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.
